Viropro Stock

Viropro ROA

The Return on Assets (ROA) of Viropro (VPRO) as of Aug 17, 2026 is -47.79 %.

ROA

-47.79 %

Last updated:

In 2026, Viropro's return on assets (ROA) was -47.79 %, a % increase from the - ROA in the previous year.

Access this data via the Eulerpool API

Viropro Stock analysis

What does Viropro do? Viropro Inc. is a pharmaceutical company specializing in the use of technologies for the production of biopharmaceutical products. Founded in 2004, the company aims to develop innovative and effective solutions for medical niche areas. The company is based in Canada and also has locations in Europe and Asia. With over 100 employees worldwide, Viropro offers a wide range of laboratory services to develop effective and safe medications. Viropro relies on a unique business model that utilizes cell culture technologies and bioreactors. They utilize a highly specialized cell preparation technology called "VIPER" which ensures the production of recombinant proteins and antibodies of the highest quality. Partnerships with other pharmaceutical and biotechnology companies are also an important aspect of Viropro's business model. They work with many companies to develop and bring medications to the market. Viropro's business activities extend to several areas within the bioproduct sector. However, the core element is the antibodies that the company produces and markets. Viropro's products also include human antibodies against cancer, HIV, and other serious diseases. Their portfolio also includes pharmacokinetic studies, antigen and peptide design services, as well as cell preparation and culture processing services. With a wide range of services and products, the company is able to develop customized solutions for the specific needs of its customers. In the field of cell preparation, Viropro primarily offers laboratory services that include a wide range of equipment and associated technologies. The VIPER technology developed by Viropro is a core component of this business unit. The peptide and antigen design unit offers services that focus on the identification and optimization of antibodies and peptides. The latest computer-based methods are used to simulate how certain proteins can develop on the computer. These methods are particularly effective in developing antibody-based medications. Finally, Viropro also offers pharmacokinetic services to ensure the safety and effectiveness of medications, as well as proper administration and dosage. Although the company is still relatively young, Viropro already has an impressive track record in the development and marketing of bioproducts. The company has brought several antibodies to the market and is contributing to providing lifesaving therapies for some of the most serious health problems of our time. Overall, Viropro is an exciting biotechnology company operating in a rapidly growing market and tackling some of the most important therapeutic challenges of our time. With the combination of innovative technologies and a flexible business model, the company is well-positioned to continue playing a leading role in the pharmaceutical and biotechnology industry. Viropro is one of the most popular companies on Eulerpool.

ROA Details

Understanding Viropro's Return on Assets (ROA)

Viropro's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Viropro's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Viropro's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Viropro’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Viropro stock

Return on Assets (ROA) of Viropro is -47.79 % in 2026.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Viropro since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Viropro with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

Profitability — Viropro

All Key Metrics — Viropro